Dallas, TX – GENESIS BIOPHARMA INCORPORATED (OTCBB: GNBP)
Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers. The Company's lead product candidate, Contego™, is a ready-to-infuse autologous cell therapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma. Contego™ is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma.
EVCARCO INCORPORATED (OTC: EVCA) "Up 50.00% in morning trading"
EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles from multiple manufactures. EVCARCO — Future Driven®
ELRAY RESOURCES INCORPORATED (OTCBB: ELRA) "Up 39.34% in morning trading"
Elray Resources, Inc. is a junior exploration and development Corporation which has successfully accumulated a portfolio of four highly prospective, heavily mineralized mining tenements in Cambodia and Mexico. Elray Resources primary objective is to source potential and viable projects, conduct geological assessments and seek Joint Venture partners to develop the properties. Elray Resources 100% controlled entity in Cambodia is Angkor Wat Minerals Ltd.
NEXT 1 INTERACTIVE INCORPORATED (OTCBB: NXOI) "Up 20.00% in morning trading"
Next One Interactive, Inc. (NXOI) is a multi-faceted media company specializing in Travel and Real Estate. Next One plans the delivery of targeted content via multiple digital platforms including Satellite, Cable, Broadcast, Broadband and mobile. In today's digital market Next One Interactive delivers information and entertainment to consumers. The company business plan calls for multiple revenue streams from real estate and travel content delivery including transactional commissions, referral fees, advertising and sponsorship. The multiple revenue streams and integrated media platforms allow for the delivery of measurable return on investment to its advertisers, sponsors and business partners.
GALENA BIOPHARMA INCORPORATED (NASDAQ: GALE) "Up 9.39% in morning trading"
Galena Biopharma, Inc., a biotechnology company, engages in discovering, developing, and commercializing innovative therapies addressing unmet medical needs using targeted bio therapeutics. The company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVax (E75), for the treatment of various cancers. It is also developing Folate Binding Protein-E39 (FBP), a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is headquartered in Lake Oswego, Oregon.
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily stock alerts go to www.otcpicks.com to sign up.
Disclosure: OTCPicks.com and affiliates have not been compensated by any of the companies covered in this release.
